Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

26 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Subcutaneous recombinant interleukin-2 (rIL-2) in out-patients with metastatic renal cell carcinoma. Results of a multicenter SCAPP1 trial.
Tourani JM, Lucas V, Mayeur D, Dufour B, DiPalma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Pujade-Lauraine E, Larregain D, Ecstein E, Untereiner M, Vuillemin E, Merran S, Andrieu JM. Tourani JM, et al. Among authors: untereiner m. Ann Oncol. 1996 Jul;7(5):525-8. doi: 10.1093/oxfordjournals.annonc.a010644. Ann Oncol. 1996. PMID: 8839910 Free article. Clinical Trial.
[Subcutaneous administration of interleukin-2 in ambulatory treatment of patients with metastatic renal cancer. Three-year results of the SCAPP I program].
Tourani JM, Jaillon-Abraham C, Lucas V, Chrétien Y, Mayeur D, Di Palma M, Boaziz C, Grise P, Varette C, Pavlovitch JM, Larregain D, Ecstein E, Untereiner M, Andrieu JM. Tourani JM, et al. Among authors: untereiner m. Bull Cancer. 1997 Apr;84(4):351-6. Bull Cancer. 1997. PMID: 9238157 Free article. Clinical Trial. French.
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group.
Tourani JM, Pfister C, Berdah JF, Benhammouda A, Salze P, Monnier A, Paule B, Guillet P, Chretien Y, Brewer Y, Di Palma M, Untereiner M, Malaurie E, Tadrist Z, Pavlovitch JM, Hauteville D, Mejean A, Azagury M, Mayeur D, Lucas V, Krakowski I, Larregain-Fournier D, Abourachid H, Andrieu JM, Chastang C. Tourani JM, et al. Among authors: untereiner m. J Clin Oncol. 1998 Jul;16(7):2505-13. doi: 10.1200/JCO.1998.16.7.2505. J Clin Oncol. 1998. PMID: 9667271 Clinical Trial.
Interleukin-2 in outpatients with renal cell carcinoma: SCAPP1 trial.
Tourani JM, Grise P, Lucas V, Mayeur D, Dufour B, Di Palma M, Boaziz C, Pavlovitch JM, Pujade-Lauraine E, Larregain D, Untereiner M. Tourani JM, et al. Among authors: untereiner m. Cancer Biother Radiopharm. 1996 Oct;11(5):297-300. doi: 10.1089/cbr.1996.11.297. Cancer Biother Radiopharm. 1996. PMID: 10851507 Clinical Trial. No abstract available.
Postoperative pelvic radiotherapy with or without elective irradiation of para-aortic nodes and liver in rectal cancer patients. A controlled clinical trial of the EORTC Radiotherapy Group.
Bosset JF, Horiot JC, Hamers HP, Cionini L, Bartelink H, Caspers R, Untereiner M, Ciambelloti E, Pierart M, Van Glabbeke M. Bosset JF, et al. Among authors: untereiner m. Radiother Oncol. 2001 Oct;61(1):7-13. doi: 10.1016/s0167-8140(01)00419-4. Radiother Oncol. 2001. PMID: 11578723 Clinical Trial.
The essential role of radiotherapy in the treatment of Merkel cell carcinoma: a study from the Rare Cancer Network.
Ghadjar P, Kaanders JH, Poortmans P, Zaucha R, Krengli M, Lagrange JL, Özsoy O, Nguyen TD, Miralbell R, Baize A, Boujelbene N, Collen T, Scandolaro L, Untereiner M, Goldberg H, Pesce GA, Anacak Y, Friedrich EE, Aebersold DM, Beer KT. Ghadjar P, et al. Among authors: untereiner m. Int J Radiat Oncol Biol Phys. 2011 Nov 15;81(4):e583-91. doi: 10.1016/j.ijrobp.2011.05.028. Epub 2011 Jul 19. Int J Radiat Oncol Biol Phys. 2011. PMID: 21775069
Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3-4 rectal cancers: results of FFCD 9203.
Gérard JP, Conroy T, Bonnetain F, Bouché O, Chapet O, Closon-Dejardin MT, Untereiner M, Leduc B, Francois E, Maurel J, Seitz JF, Buecher B, Mackiewicz R, Ducreux M, Bedenne L. Gérard JP, et al. Among authors: untereiner m. J Clin Oncol. 2006 Oct 1;24(28):4620-5. doi: 10.1200/JCO.2006.06.7629. J Clin Oncol. 2006. PMID: 17008704 Clinical Trial.
Radiotherapy equipment and departments in the European countries: final results from the ESTRO-HERO survey.
Grau C, Defourny N, Malicki J, Dunscombe P, Borras JM, Coffey M, Slotman B, Bogusz M, Gasparotto C, Lievens Y; HERO consortium; Kokobobo A, Sedlmayer F, Slobina E, Feyen K, Hadjieva T, Odrazka K, Grau Eriksen J, Jaal J, Bly R, Chauvet B, Willich N, Polgar C, Johannsson J, Cunningham M, Magrini S, Atkocius V, Untereiner M, Pirotta M, Karadjinovic V, Levernes S, Sladowski K, Lurdes Trigo M, Šegedin B, Rodriguez A, Lagerlund M, Pastoors B, Hoskin P, Vaarkamp J, Cleries Soler R. Grau C, et al. Among authors: untereiner m. Radiother Oncol. 2014 Aug;112(2):155-64. doi: 10.1016/j.radonc.2014.08.029. Epub 2014 Oct 31. Radiother Oncol. 2014. PMID: 25443859 Free article.
26 results